



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/632,428-Conf. #4377		
		Filing Date	August 1, 2003		
		First Named Inventor	David Bebbington		
		Art Unit	1624		
		Examiner Name	J. H. Johnsen		
Sheet	1	of	1	Attorney Docket Number	030682.0001-US01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
WJR	AA*	US-6,841,579-B1	01-11-2005	Plowman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
WJR	BA	EP-0 019 811-A1	12-10-1980	CIBA-GEIGY AG		
	BB	GB-2 052 487-A	01-28-1981	CIBA-GEIGY AG		✓
	BC	EP-0 302 312-A2	02-08-1989	Bayer AG		
	BD	WO-WO 95/09851-A1	04-13-1995	CIBA-GEIGY AG		✓
	BE	WO-WO 97/09325-A1	03-13-1997	Signal Pharmaceuticals, Inc.		✓
	BF	WO-WO 97/19065-A1	05-29-1997	Celltech Therapeutics Limited		✓
	BG	WO-WO 98/11095-A1	03-19-1998	Celltech Therapeutics Limited		✓
	BH	WO-WO 98/38171-A1	09-03-1998	Signal Pharmaceuticals, Inc.		✓
	BI	WO-WO 99/41253-A1	08-19-1999	Tularik Inc.		✓
	BJ	WO-WO 01/40215-A1	06-07-2001	Pfizer Products Inc.		✓
WJR	BK	WO-WO 01/47897-A1	07-05-2001	Pharmacopeia, Inc. and Bristol-Myers Squibb Company		✓
WJR	BL	WO-WO 01/79198-A1	10-25-2001	Agouron Pharmaceuticals, Inc.		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/25/06
-----------------------	--	--------------------	----------


Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned 10/632,428
	Filing Date	Herewith 8/1/2003
	First Named Inventor	David Bebbington
	Group Art Unit	Sudhaker B. Patel
	Examiner Name	1624
	Attorney Docket Number	VPI/00-130-03 CON US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
JJ	A1*	US 2001/0018436	30-Aug-2001	Tularik Inc.			
JJ	A2*	2002/0065270	05/30/2002	Bristol-Myers Squibb Company			
JJ	A3*	USSN 10/025,164	12/2001	Vertex Pharmaceuticals Incorporated			19-Dec-2001

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
GG	B1*		WO 02/18346	Pfizer Products, Inc.	07-Mar-2002		
HH	B2*		WO 00/39101	Astrazeneca UK Limited	06-Jul-2000		
BB	B3*		WO 00/21955	Zeneca Limited	20-Apr-2000		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/025,164, filed December 19, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications)

Examiner Signature		Date Considered	2/2/06
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.